High-dose clevudine impairs mitochondrial function and glucose-stimulated insulin secretion in INS-1E cells

BMC Gastroenterology

Volumn 12, Issue , 2012, Pages

  Jang, Yoon Ok ^a   Quan, Xianglan ^a   Das, Ranjan ^a   Xu, Shanhua ^a   Chung, Choon Hee ^a   Ahn, Chan Mug ^a   Baik, Soon Koo ^a   Kong, In Deok ^a   Park, Kyu Sang ^a   Kim, Moon Young ^a  

^a Yonsei University Wonju   (South Korea)

Author keywords

Clevudine; Glucose stimulated insulin secretion; Mitochondrial DNA; Mitochondrial dysfunction

Indexed keywords

CLEVUDINE; CYCLOOXYGENASE 1; CYTOCHROME C OXIDASE; GLUCOSE; LACTIC ACID; MESSENGER RNA; MITOCHONDRIAL DNA; REVOVIR; UNCLASSIFIED DRUG; 2'-FLUORO-5-METHYLARABINOSYLURACIL; ADENOSINE TRIPHOSPHATE; ANTIVIRUS AGENT; DRUG DERIVATIVE; INSULIN; LACTIC ACID DERIVATIVE; URACIL ARABINOSIDE;

ANIMAL CELL; ARTICLE; CELL ACTIVITY; CELL FUNCTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA CONTENT; DNA REPLICATION; DRUG EFFICACY; ENZYME ACTIVITY; FATTY ACID OXIDATION; GENE DOSAGE; HUMAN; HUMAN CELL; INSULIN RELEASE; MITOCHONDRION; NONHUMAN; NUCLEOTIDE SEQUENCE; RAT; ANIMAL; CELL LINE; CELL STRAIN HEPG2; COPY NUMBER VARIATION; CYTOLOGY; DOSE RESPONSE; DRUG EFFECT; METABOLISM; PANCREAS ISLET BETA CELL; PHYSIOLOGY;

ADENOSINE TRIPHOSPHATE; ANIMALS; ANTIVIRAL AGENTS; ARABINOFURANOSYLURACIL; CELL LINE; DNA COPY NUMBER VARIATIONS; DNA, MITOCHONDRIAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRON TRANSPORT COMPLEX IV; GLUCOSE; HEP G2 CELLS; HUMANS; INSULIN; INSULIN-SECRETING CELLS; LACTATES; MITOCHONDRIA; RATS; RNA, MESSENGER;

EID: 84862816077     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-12-4     Document Type: Article

References (36)

1. Sorrell MF, Belongia EA, Costa J, Gareen IF, Grem JL, Inadomi JM, Kern ER, McHugh JA, Petersen GM, Rein MF, et al. National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. Ann Intern Med 2009, 150(2):104-110.
2. Balakrishna Pai S, Liu SH, Zhu YL, Chu CK, Cheng YC. Inhibition of hepatitis B virus by a novel L-nucleoside, 2'-fluoro-5-methyl-beta-L-arabinofuranosyl uracil. Antimicrobial agents and chemotherapy 1996, 40(2):380-386. 163120, 8834884.
3. Mallon PW, Unemori P, Sedwell R, Morey A, Rafferty M, Williams K, Chisholm D, Samaras K, Emery S, Kelleher A, et al. In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA. J Infect Dis 2005, 191(10):1686-1696. 10.1086/429697, 15838796.
4. Lewis W, Day BJ, Copeland WC. Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat Rev Drug Discov 2003, 2(10):812-822. 10.1038/nrd1201, 14526384.
5. Yao GQ, Liu SH, Chou E, Kukhanova M, Chu CK, Cheng YC. Inhibition of Epstein-Barr virus replication by a novel L-nucleoside, 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil. Biochem Pharmacol 1996, 51(7):941-947. 10.1016/0006-2952(96)00049-4, 8651944.
6. Kwon SY, Park YK, Ahn SH, Cho ES, Choe WH, Lee CH, Kim BK, Ko SY, Choi HS, Park ES, et al. Identification and characterization of clevudine-resistant mutants of hepatitis B virus isolated from chronic hepatitis B patients. J Virol 2010, 84(9):4494-4503. 10.1128/JVI.02066-09, 2863790, 20164224.
7. Seok JI, Lee DK, Lee CH, Park MS, Kim SY, Kim HS, Jo HY, Kim DS. Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA. Hepatology 2009, 49(6):2080-2086. 10.1002/hep.22959, 19333909.
8. Tak WY, Park SY, Jung MK, Jeon SW, Cho CM, Kweon YO, Kim SK, Choi YH. Mitochondrial myopathy caused by clevudine therapy in chronic hepatitis B patients. Hepatol Res 2009, 39(9):944-947. 10.1111/j.1872-034X.2009.00515.x, 19712273.
9. Jang JH, Kim JW, Jeong SH, Myung HJ, Kim HS, Park YS, Lee SH, Hwang JH, Kim N, Lee DH. Clevudine for chronic hepatitis B: antiviral response, predictors of response, and development of myopathy. J Viral Hepat 2011, 18(2):84-90. 10.1111/j.1365-2893.2010.01281.x, 20196804.
10. Tak WY, Park SY, Cho CM, Jung MK, Jeon SW, Kweon YO, Park JY, Sohn YK. Clinical, biochemical, and pathological characteristics of clevudine-associated myopathy. J Hepatol 2010, 53(2):261-266. 10.1016/j.jhep.2010.03.006, 20466447.
11. Wiederkehr A, Wollheim CB. Minireview: implication of mitochondria in insulin secretion and action. Endocrinology 2006, 147(6):2643-2649. 10.1210/en.2006-0057, 16556766.
12. Kim GW, Lee MY, Kim SY, Kim JH, Lee JH, Chung CH. Clevudine induced diabetes mellitus in a patient with chronic hepatitis B. Korean J Med 2010, 79(5):569-572.
13. Nolan D, Hammond E, Martin A, Taylor L, Herrmann S, McKinnon E, Metcalf C, Latham B, Mallal S. Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy. AIDS 2003, 17(9):1329-1338. 10.1097/00002030-200306130-00007, 12799554.
14. Miura T, Goto M, Hosoya N, Odawara T, Kitamura Y, Nakamura T, Iwamoto A. Depletion of mitochondrial DNA in HIV-1-infected patients and its amelioration by antiretroviral therapy. J Med Virol 2003, 70(4):497-505. 10.1002/jmv.10423, 12794710.
15. Stankov MV, Lucke T, Das AM, Schmidt RE, Behrens GM. Relationship of mitochondrial DNA depletion and respiratory chain activity in preadipocytes treated with nucleoside reverse transcriptase inhibitors. Antivir Ther 2007, 12(2):205-216.
16. Barrientos A. In vivo and in organello assessment of OXPHOS activities. Methods 2002, 26(4):307-316. 10.1016/S1046-2023(02)00036-1, 12054921.
17. Miro O, Cardellach F, Barrientos A, Casademont J, Rotig A, Rustin P. Cytochrome c oxidase assay in minute amounts of human skeletal muscle using single wavelength spectrophotometers. Journal of neuroscience methods 1998, 80(1):107-111. 10.1016/S0165-0270(97)00204-5, 9606056.
18. Park KS, Wiederkehr A, Kirkpatrick C, Mattenberger Y, Martinou JC, Marchetti P, Demaurex N, Wollheim CB. Selective actions of mitochondrial fission/fusion genes on metabolism-secretion coupling in insulin-releasing cells. J Biol Chem 2008, 283(48):33347-33356. 10.1074/jbc.M806251200, 2662262, 18832378.
19. Fromenty B, Pessayre D. Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharmacology & therapeutics 1995, 67(1):101-154. 10.1016/0163-7258(95)00012-6, 22235437.
20. Igoudjil A, Massart J, Begriche K, Descatoire V, Robin MA, Fromenty B. High concentrations of stavudine impair fatty acid oxidation without depleting mitochondrial DNA in cultured rat hepatocytes. Toxicology in vitro: an international journal published in association with BIBRA 2008, 22(4):887-898.
21. Kennedy ED, Maechler P, Wollheim CB. Effects of depletion of mitochondrial DNA in metabolism secretion coupling in INS-1 cells. Diabetes 1998, 47(3):374-380. 10.2337/diabetes.47.3.374, 9519742.
22. Maassen JA, Janssen GM, t Hart LM. Molecular mechanisms of mitochondrial diabetes (MIDD). Ann Med 2005, 37(3):213-221. 10.1080/07853890510007188, 16019720.
23. Deng S, Vatamaniuk M, Huang X, Doliba N, Lian MM, Frank A, Velidedeoglu E, Desai NM, Koeberlein B, Wolf B, et al. Structural and functional abnormalities in the islets isolated from type 2 diabetic subjects. Diabetes 2004, 53(3):624-632. 10.2337/diabetes.53.3.624, 14988246.
24. Pinti M, Salomoni P, Cossarizza A. Anti-HIV drugs and the mitochondria. Biochim Biophys Acta 2006, 1757(5-6):700-707. 10.1016/j.bbabio.2006.05.001, 16782042.
25. Lim SE, Copeland WC. Differential incorporation and removal of antiviral deoxynucleotides by human DNA polymerase gamma. J Biol Chem 2001, 276(26):23616-23623. 10.1074/jbc.M101114200, 11319228.
26. Fleischer RD, Lok AS. Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B. J Hepatol 2009, 51(4):787-791. 10.1016/j.jhep.2009.06.011, 19665816.
27. Kim HJ, Park DI, Park JH, Cho YK, Sohn CI, Jeon WK, Kim BI. Comparison between clevudine and entecavir treatment for antiviral-naive patients with chronic hepatitis B. Liver Int 2010, 30(6):834-840.
28. Cunha DA, Hekerman P, Ladriere L, Bazarra-Castro A, Ortis F, Wakeham MC, Moore F, Rasschaert J, Cardozo AK, Bellomo E, et al. Initiation and execution of lipotoxic ER stress in pancreatic beta-cells. Journal of cell science 2008, 121(Pt 14):2308-2318.
29. Rossignol R, Faustin B, Rocher C, Malgat M, Mazat JP, Letellier T. Mitochondrial threshold effects. The Biochemical journal 2003, 370(Pt 3):751-762. 1223225, 12467494.
30. Pan-Zhou XR, Cui L, Zhou XJ, Sommadossi JP, Darley-Usmar VM. Differential effects of antiretroviral nucleoside analogs on mitochondrial function in HepG2 cells. Antimicrobial agents and chemotherapy 2000, 44(3):496-503. 10.1128/AAC.44.3.496-503.2000, 89717, 10681309.
31. Niu C, Murakami E, Furman PA. Clevudine is efficiently phosphorylated to the active triphosphate form in primary human hepatocytes. Antivir Ther 2008, 13(2):263-269.
32. Yamanaka H, Gatanaga H, Kosalaraksa P, Matsuoka-Aizawa S, Takahashi T, Kimura S, Oka S. Novel mutation of human DNA polymerase gamma associated with mitochondrial toxicity induced by anti-HIV treatment. J Infect Dis 2007, 195(10):1419-1425. 10.1086/513872, 17436221.
33. Chan SS, Copeland WC. DNA polymerase gamma and mitochondrial disease: understanding the consequence of POLG mutations. Biochim Biophys Acta 2009, 1787(5):312-319. 10.1016/j.bbabio.2008.10.007, 2742478, 19010300.
34. Wang CH, Wang CC, Wei YH. Mitochondrial dysfunction in insulin insensitivity: implication of mitochondrial role in type 2 diabetes. Ann N Y Acad Sci 2010, 1201:157-165. 10.1111/j.1749-6632.2010.05625.x, 20649552.
35. Lebrecht D, Vargas-Infante YA, Setzer B, Kirschner J, Walker UA. Uridine supplementation antagonizes zalcitabine-induced microvesicular steatohepatitis in mice. Hepatology 2007, 45(1):72-79. 10.1002/hep.21490, 17187420.
36. Lebrecht D, Deveaud C, Beauvoit B, Bonnet J, Kirschner J, Walker UA. Uridine supplementation antagonizes zidovudine-induced mitochondrial myopathy and hyperlactatemia in mice. Arthritis and rheumatism 2008, 58(1):318-326. 10.1002/art.23235, 18163507.